Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.47 |
| ▸ | HRH1 | P35367 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904176 | 0.86 | HRH3 (0.48) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904045 | 0.83 | HRH3 (0.53) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904174 | 0.83 | HRH3 (0.48) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| Hydrochloric Acid SCHEMBL5904068 | 0.83 | HRH3 (0.55) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904196 | 0.81 | HRH3 (0.52) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904357 | 0.81 | SIGMAR1 (0.57) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904106 | 0.81 | HRH3 (0.51) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904150 | 0.80 | HRH3 (0.47) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| Hydrochloric Acid SCHEMBL5904107 | 0.80 | HRH3 (0.55) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904110 | 0.79 | HRH3 (0.56) | HRH3HRH1SIGMAR1BACE1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006046131-A1 | TETRALIN HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-05-04 | — | — | WO | claimed |
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | PFIZER INC | 2006-05-04 | — | — | US | claimed |
| WO-2006046131-A1 | TETRALIN HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | PFIZER INC | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885SIGMAR1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.